FRAXA funds Quiver Biosciences to validate a novel antisense oligonucleotide (ASO) therapy for Fragile X syndrome, targeting the root cause of the disorder.
Read more
FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome
Accelerating Fragile X Research for Effective Treatments